287 related articles for article (PubMed ID: 32804353)
1. How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support.
Berkowitz MJ; Thompson CK; Zibecchi LT; Lee MK; Streja E; Berkowitz JS; Wenziger CM; Baker JL; DiNome ML; Attai DJ
J Cancer Surviv; 2021 Feb; 15(1):29-39. PubMed ID: 32804353
[TBL] [Abstract][Full Text] [Related]
2. A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer.
Harrow A; Dryden R; McCowan C; Radley A; Parsons M; Thompson AM; Wells M
BMJ Open; 2014 Jun; 4(6):e005285. PubMed ID: 24928595
[TBL] [Abstract][Full Text] [Related]
3. The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation.
Gomaa S; Lopez A; Slamon R; Smith R; Lapitan E; Nightingale G; Miller SM; Wen KY
Support Care Cancer; 2023 Nov; 31(12):719. PubMed ID: 38008817
[TBL] [Abstract][Full Text] [Related]
4. Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer.
Wassermann J; Gelber SI; Rosenberg SM; Ruddy KJ; Tamimi RM; Schapira L; Borges VF; Come SE; Meyer ME; Partridge AH
Cancer; 2019 Sep; 125(18):3266-3274. PubMed ID: 31120571
[TBL] [Abstract][Full Text] [Related]
5. [Aromatase inhibitors and arthralgia].
Nagykálnai T; Landherr L; Mészáros E
Magy Onkol; 2011 Mar; 55(1):32-9. PubMed ID: 21617789
[TBL] [Abstract][Full Text] [Related]
6. Adherence to Adjuvant Endocrine Therapy in Women With Breast Cancer: A Prospective Observational Study in Japanese Women.
Kuba S; Maeda S; Matsumoto M; Yamanouchi K; Yano H; Morita M; Sakimura C; Hatachi T; Tokai Y; Takatsuki M; Fujioka H; Hayashida N; Nagayasu T; Eguchi S
Clin Breast Cancer; 2018 Apr; 18(2):150-156. PubMed ID: 29290564
[TBL] [Abstract][Full Text] [Related]
7. Adherence to long-term adjuvant hormonal therapy for breast cancer.
Gotay C; Dunn J
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-15. PubMed ID: 22098287
[TBL] [Abstract][Full Text] [Related]
8. Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer.
Bright EE; Petrie KJ; Partridge AH; Stanton AL
Breast Cancer Res Treat; 2016 Jul; 158(2):243-51. PubMed ID: 27342455
[TBL] [Abstract][Full Text] [Related]
9. Managing side effects in adjuvant endocrine therapy for breast cancer.
Condorelli R; Vaz-Luis I
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1101-1112. PubMed ID: 30188738
[TBL] [Abstract][Full Text] [Related]
10. Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: A 5-year prospective study.
Hagen KB; Aas T; Kvaløy JT; Søiland H; Lind R
Breast; 2019 Apr; 44():52-58. PubMed ID: 30641300
[TBL] [Abstract][Full Text] [Related]
11. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.
Garreau JR; Delamelena T; Walts D; Karamlou K; Johnson N
Am J Surg; 2006 Oct; 192(4):496-8. PubMed ID: 16978958
[TBL] [Abstract][Full Text] [Related]
12. Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up.
Simon R; Latreille J; Matte C; Desjardins P; Bergeron E
Can J Surg; 2014 Feb; 57(1):26-32. PubMed ID: 24461223
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences.
Hayes DF
Breast; 2015 Nov; 24 Suppl 2():S6-S10. PubMed ID: 26238437
[TBL] [Abstract][Full Text] [Related]
14. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
Perez EA
Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
[TBL] [Abstract][Full Text] [Related]
15. [Management of side effects related to adjuvant hormone therapy in young women with breast cancer].
Saghatchian M; Lesur A
Bull Cancer; 2019 Dec; 106(12S1):S37-S42. PubMed ID: 32008736
[TBL] [Abstract][Full Text] [Related]
16. The importance of nonpharmacogenetic factors in endocrine therapy.
McCowan C; Thompson AM
Pharmacogenomics; 2012 Apr; 13(6):721-8. PubMed ID: 22515614
[TBL] [Abstract][Full Text] [Related]
17. Extended Endocrine Therapy: Is 5 Years Enough?
Bhave MA; Henry NL
Curr Oncol Rep; 2017 Mar; 19(3):16. PubMed ID: 28251491
[TBL] [Abstract][Full Text] [Related]
18. The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study.
Frechette D; Paquet L; Verma S; Clemons M; Wheatley-Price P; Gertler SZ; Song X; Graham N; Dent S
Breast Cancer Res Treat; 2013 Aug; 141(1):111-7. PubMed ID: 23942873
[TBL] [Abstract][Full Text] [Related]
19. Perceptions, Attributions, and Emotions Toward Endocrine Therapy in Young Women with Breast Cancer.
Walker HE; Rosenberg SM; Stanton AL; Petrie KJ; Partridge AH
J Adolesc Young Adult Oncol; 2016 Mar; 5(1):16-23. PubMed ID: 26812461
[TBL] [Abstract][Full Text] [Related]
20. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy.
Cella D; Fallowfield LJ
Breast Cancer Res Treat; 2008 Jan; 107(2):167-80. PubMed ID: 17876703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
